Replicate Bioscience
Replicate Bioscience is a clinical-stage biotechnology company developing self-replicating RNA (srRNA) technology to enhance the effectiveness of RNA-based therapeutics beyond traditional mRNA approaches. Its platform is designed to deliver stronger biological activity, more durable immune responses, and an improved therapeutic index. The company’s lead program, RBI-4000, an srRNA-based rabies vaccine, has shown protective immunity at lower doses than any mRNA or srRNA vaccine reported to date in Phase I studies. Backed by Apple Tree Partners, Replicate is building a diverse pipeline of srRNA vaccines and therapeutics supported by a proprietary, customizable viral vector library. With extensive expertise in srRNA and integrated development capabilities, the company aims to broaden the application of RNA therapies across infectious diseases, immunology, and immuno-oncology.
Domain
replicatebioscience.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$7.0M
Founded
2019
Tech Stack (17 technologies)
Frequently Asked Questions
What technologies does Replicate Bioscience use?+
Replicate Bioscience uses 17 technologies including Google Analytics, Google Tag Manager, WordPress.
What industry is Replicate Bioscience in?+
Replicate Bioscience operates in the Biotechnology industry.
Where is Replicate Bioscience based?+
Replicate Bioscience is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026